|
Triall (TRL) |
Status
ICO
IDO
Triall’s mission is to accelerate the introduction of safe and affordable vaccines and therapeutics into society by streamlining clinical trials.
Important By investing in this business you agree to ourDisclaimer. All information including our rating, is provided merely for informational purposes. CryptoTotem does not provide investment advice.
What is Triall
Triall is laying the groundwork for tomorrow’s digital playing field in clinical trials. We bring Web 3.0 to medical research by developing a digital ecosystem of blockchain-integrated software solutions. Our blockchain infrastructure makes medical data tamper-resistant. It also enables secure and efficient connections between the many isolated systems and parties involved in clinical research. Our mission is to accelerate the introduction of safe and affordable vaccines and therapeutics into society by streamlining clinical trials. We bring Web 3.0 to medical research, by realizing a digital ecosystem for clinical trials. What are the unique benefits of the Triall ecosystem?-
- System Integration & Interoperability
-
- Efficiency & Operational Excellence
-
- Data integrity & Auditability
- Availability & Ease of Use
Token Sale Dates
IDO
Start date: Sep 28, 2021
End date: Sep 28, 2021
IDO
Start date: Sep 28, 2021
End date: Sep 28, 2021
Token Allocation
Total Token Supply 175,000,000 TRL
Total Tokens for Sale 18,250,000 TRL
Funding Details
Hard Cap 2,993,750 USD
Funds allocation
Liquidity, long-term operations & development - 8%
18% - Pre-sale
24% - Treasury
10% - Triall Community Fund
12,5% - Existing investors
8% - Advisors
10% - Founding team
9,5% - Growth, acquisition & marketing
Token Price and Payment Options
Token price USD 1 TRL = 0,2 USD
Accepted Currencies USDT
Project team
Hadil Es-Sbai, MSc
President | CEO
Niels Klomp, MSc
CTO
Dr. Linda van de Burgwal
CFO
Rob Posthumus, LL.M.
General Counsel
Raymond van der Waal, MSc
Head of Marketing
Dr. Joost Flach
Head of Clinical Affairs
Mark van der Waal, MSc
Head of Product
Advisors
Sina Djali
Head of Integrated Data Analytics Janssen Pharmaceuticals (J&J)
Danielle Bradbury
VP Quality Assurance Galera Therapeutics
Prof. Niels Chavannes, MD, PhD
Head of Research, Public Health & Primary Care Leiden University Medical Center
Cari Jacobs Blom
Director Quality & Compliance CR2O
Prof. Sjaak Bloem, PhD
Associate Director Behavioral Science Janssen Pharmaceuticals (J&J)
Allan Bukuya
COO TrialDocs International
Nick van den Bulk
Head Clinical Operations CR2O
Prof. Eric Claassen, PhD
Sequential Biotech Entrepreneur & Angel Investor Multiple ventures










One Response
i like this project nice that i have invet in this project